Here are the top movers in Tuesday's session. Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions.
Let's have a look at the top gainers and losers in the middle of the day of today's session. Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
There are notable gap-ups and gap-downs in today's session. In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q2 2024 NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024 NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023 NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio Stocks for financial freedom are generational companies that are well-run, growing fast, and focused on the future.
Earnings Scheduled For March 5, 2024 Companies Reporting Before The Bell • NIO (
NYSE:NIO ) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
